Target Antigen
AVEN
AVEN Antibody, ALEXA FLUOR 594
Description:
Size: 100ul
Catalog no.: bs-2438R-A594
Price: 380 EUR
Product details
Modification Site
None
Gene ID Number
57099
Tested applications
IF(IHC-P)
French translation
anticorps
Modification
Unmodified
Clonality
Polyclonal
Excitation emission
590nm/617nm
Concentration
1ug per 1ul
Crossreactivity
Human, Mouse, Rat
Conjugated with
ALEXA FLUOR® 594
Conjugated
Alexa conjugate 1
Recommended dilutions
IF(IHC-P)(1:50-200)
Clone
Polyclonal antibody
Purification
Purified by Protein A.
Category
Conjugated Primary Antibodies
Also known as
Anti-AVEN PAb ALEXA FLUOR 594
Conjugation
Alexa Fluor,ALEXA FLUOR® 594
Host Organism
Rabbit (Oryctolagus cuniculus)
Specificity
This is a highly specific antibody against AVEN.
Long name
AVEN Polyclonal Antibody, ALEXA FLUOR 594 Conjugated
Cross-reactive species details
Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.
Source
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human AVEN
Storage conditions
Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.
Synonyms
1700013A01Rik; 1700056A21Rik; mAven L; mAven S; MGC124011; Apoptosis caspase activation inhibitor; Cell death regulator Aven; OTTMUSP00000016129; PDCD12; Programmed cell death 12; RP23-52C15.2; AVEN_HUMAN
Properties
For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.
Background of the antigen
Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. AVEN is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that AVEN functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that AVEN impedes Apaf-1-mediated caspase activation. Higher levels of AVEN mRNA are seen in patients with acute leukemia than in control patients, suggesting that AVEN may be useful as a prognostic indicator in leukemia patients.